Nifedipine Retard Was as Effective as Angiotensin Converting Enzyme Inhibitors in Preventing Cardiac Events in High-Risk Hypertensive Patients with Diabetes and Coronary Artery Disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Subgroup Analysis

1,650 hypertensive patients with coronary artery disease (CAD defined as ≧75% stenosis on coronary arteriography or diagnosed myocardial ischemia), stratified by diabetes status (372 diabetic, 1,278 nondiabetic). Mean age ~64 years, ~68% male, Japan-based. Hypertension criteria: SBP ≧160 mmHg or DBP ≧95 mmHg, or SBP ≧150 mmHg and DBP ≧90 mmHg.

Nifedipine retard (long-acting nifedipine formulation) 20-40 mg/day oral for 3 years, with a target blood pressure below 150/90 mmHg.

Angiotensin converting enzyme (ACE) inhibitor (enalapril 5-10 mg/day, imidapril 5-10 mg/day, or lisinopril 10-20 mg/day) oral for 3 years, with a target blood pressure below 150/90 mmHg.

Overall incidence of cardiac events (composite of cardiac death or sudden death, myocardial infarction, angina pectoris requiring hospitalization, heart failure requiring hospitalization, serious arrhythmia, or performance of coronary interventions) over a 3-year period.composite